Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC
EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC
EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
Now Viewing
EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
EP: 7.Final Insights on Current Bladder Cancer Clinical Trials
Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Related Videos
Related Content
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024Podcast
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
